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Letter to the Editor
On the cost-utility of methylene blue-photoinactivated plasma 
versus quarantine plasma in Spain
Arturo Pereira1, Julio del Río-Garma2, José A. García-Erce3
1Hospital Clínic, Barcelona; 2Ourense University Hospital Complex, Ourense; 3Navarra Blood and Tissue Bank, 
Pamplona, Spain
Dear Sir,
In the report on the cost-utility of methylene blue-
photoinactivated plasma (MBPIP) versus quarantine 
plasma (QP) in Spain, Babigumira et al.1 assume that 
MBPIP is more effective than QP. We would like to 
point out that such assumption is based on an incomplete 
evaluation of all the available data.
Studies conducted in Spain and elsewhere have 
shown that MBPIP is actually less effective than QP in 
some of the main indications for plasma transfusion. 
In thrombotic thrombocytopenic purpura, the use of 
MBPIP as the replacement fluid for plasma exchange 
yielded worse clinical results than QP2. In a large 
university hospital in Spain, the introduction of MBPIP 
increased the demand for plasma and plasma derivatives, 
probably to compensate for the reduced haemostatic 
capacity of MBPIP3. In a model of massive transfusion 
in trauma patients, pathogen-inactivated blood products 
- including plasma - were linked to poorer outcomes and 
increased transfusion4. 
We conjecture that had the authors took into account 
these data, then QP would have dominated MBPIP in 
most scenarios. Moreover, inclusion of additional costs 
derived from the increased compensatory demand for 
plasma and plasma derivatives would have turned the 
cost equation against MBPIP in all scenarios. Lack 
of consideration of the above cited reports, even in 
sensitivity analyses, has unfairly biased the conclusion 
by Babigumira et al.1 against QP.
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